Human Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic Structure
about
Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 EnvViral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization BreadthFunctional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individualsRabbit Anti-HIV-1 Monoclonal Antibodies Raised by Immunization Can Mimic the Antigen-Binding Modes of Antibodies Derived from HIV-1-Infected HumansThermodynamic Signatures of the Antigen Binding Site of mAb 447–52D Targeting the Third Variable Region of HIV-1 gp120A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C.Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization.A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cellsAbility to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire.Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFLProduction and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individualsHIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.Ro52 autoantibodies arise from self-reactive progenitors in a mother of a child with neonatal lupus.HIV-1 Cross-reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Non-human Primate.Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity.Conference report: "Functional Glycomics in HIV Type 1 Vaccine Design" workshop report, Bethesda, Maryland, April 30-May 1, 2012.Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials.A murine Ig light chain transgene reveals IGKV3 gene contributions to anti-collagen types IV and II specificities.Increased epitope complexity correlated with antibody affinity maturation and a novel binding mode revealed by structures of rabbit antibodies against the third variable loop (V3) of HIV-1 gp120.A common antigenic motif recognized by naturally occurring human VH5-51/VL4-1 anti-tau antibodies with distinct functionalities.
P2860
Q27644383-41EE3C2D-0832-4D85-92C5-8087FAA7151BQ27676728-7880A0E6-AE8C-4F79-B9F0-895E4CE057C3Q27677941-740C5305-F82D-4C44-A1A7-63C87E7B59F9Q27679123-75059427-E506-497E-AF2A-1E0E648F972BQ27679559-390981C5-393E-4438-AF59-1597F72A0D92Q34478387-F8026C6A-4C49-410D-B56C-E8A0C3650BE9Q35168642-2F200A21-956A-4FD4-A9B2-29E44D123C41Q35691113-C9BCB87E-87C8-40AF-8D32-B8EF53560ACFQ35706462-BF8748E3-8AE5-4C43-82A3-24698D111D4CQ35737800-311AA0B8-CF2E-4F60-9571-2917D5480642Q35883727-1097AF24-2C29-408C-909F-771D5B76E151Q35913910-363F080C-AF7B-45C9-82CE-B1CA866ECF77Q36384117-AC826088-54DB-428B-B792-E01A2EC1A7C8Q36920319-12E66382-F5E3-4A5F-8BC8-9AE4054F90F1Q37130745-34E16D45-7323-4702-B2D6-803A370AFC56Q37293480-7E67B2CA-49D2-42BE-BE4A-6B6F40672B29Q38968180-C915F822-A2BD-4BF8-A51F-A121E1515785Q39001406-C52A9A5C-D13B-499A-AD3D-0B0AD2BCC093Q40073016-EB6C7E7B-0D94-4013-839D-9F35FCE98676Q40301176-A3F67054-F805-43D1-8865-B21F069F0147Q42933039-1FFA7C3C-0ABF-4D39-9DB4-2C52DCA8D18CQ47555452-3532B6FF-95A9-41C0-AEE2-49E8265686A2Q47833098-F2B632B6-3A36-4906-A4D9-1F2EA33AD9B0Q49990084-C0291CED-2820-4F88-AA79-7666C6E33634Q55238549-DFD42AD6-E27F-48A2-92A9-CB96FD4CAF91
P2860
Human Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic Structure
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Human Anti-V3 HIV-1 Monoclonal ...... Conserved Antigenic Structure
@ast
Human Anti-V3 HIV-1 Monoclonal ...... Conserved Antigenic Structure
@en
Human Anti-V3 HIV-1 Monoclonal ...... Conserved Antigenic Structure
@nl
type
label
Human Anti-V3 HIV-1 Monoclonal ...... Conserved Antigenic Structure
@ast
Human Anti-V3 HIV-1 Monoclonal ...... Conserved Antigenic Structure
@en
Human Anti-V3 HIV-1 Monoclonal ...... Conserved Antigenic Structure
@nl
altLabel
Human anti-V3 HIV-1 monoclonal ...... conserved antigenic structure
@en
prefLabel
Human Anti-V3 HIV-1 Monoclonal ...... Conserved Antigenic Structure
@ast
Human Anti-V3 HIV-1 Monoclonal ...... Conserved Antigenic Structure
@en
Human Anti-V3 HIV-1 Monoclonal ...... Conserved Antigenic Structure
@nl
P2093
P2860
P50
P3181
P1433
P1476
Human anti-V3 HIV-1 monoclonal ...... conserved antigenic structure
@en
P2093
Barbara Volsky
Constance Williams
Huiguang Li
Maxim Totrov
Phillipe Nyambi
Susan Zolla-Pazner
Timothy Cardozo
Timothy O'Neal
Xiao-Hong Wang
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0027780
P407
P577
2011-12-02T00:00:00Z